Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease

Status: Completed
Location: See location...
Intervention Type: Radiation
Study Type: Observational
SUMMARY

This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the effectiveness of bevacizumab.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No
View:

• Age between 18 and 80 years of age

• Progressive glioblastoma patients who have been planned to receive bevacizumab

• Karnofsky Performance Status 50 or above (vd. Appendix A)

• Established pathologic diagnosis of glioblastoma

• Prior treatment with radiation and chemotherapy

• Neuroimaging progression of glioblastoma

• Able and willing to provide informed consent (or consent of a guardian)

Locations
United States
South Carolina
Medical University of South Carolina
Charleston
Time Frame
Start Date: July 2012
Completion Date: September 2014
Participants
Target number of participants: 13
Treatments
glioblastoma patients on bevacizumab
Sponsors
Leads: Medical University of South Carolina

This content was sourced from clinicaltrials.gov

Similar Clinical Trials